medRxiv preprint doi: https://doi.org/10.1101/2021.04.02.21254838; this version posted April 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies David E. Garda, Mollie M. Pleetb, c, Ellen R. Bradleyb, c, Andrew Pennb, Matthew L. Gallensteina, Lauren S. Rileya, Meghan DellaCrossed, Emily Garfinklee, Erin E. Michalakf, Joshua D. Woolleyb, c aSan Francisco State University, San Francisco, CA USA bUniversity of California San Francisco, San Francisco, CA USA cSan Francisco Veteran's Affairs Medical Center, San Francisco, CA USA dThe Wright Institute, Berkeley, CA USA ePalo Alto University-Pacific Graduate School of Psychology, Palo Alto, CA USA fUniversity of British Columbia, Vancouver, BC Canada Corresponding author: David E. Gard, Ph.D. Department of Psychology, San Francisco State University 1600 Holloway Ave San Francisco, California 94132 USA
[email protected] Sources of direct funding, support, or sponsorship ● Dr. Woolley is funded in part via VA CSR&D 1IK4CX002090-01. Grant title: Quantifying and Treating Social Deficits in Veterans with Mental Illness: a Five Year Plan. Role of the sponsor ● Not applicable Potential conflicts of interest ● Dr. Woolley is a paid consultant for Psilo Scientific Ltd. and Silo Pharma. Abstract: 250 words Text: 4998 words Number of Figures: 1 Number of Tables: 2 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.